Skip to search formSkip to main contentSkip to account menu

RX-3117

Known as: Cytidine Analog RX-3117 
An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, the cytidine analog RX… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
ABSTRACT Introduction: RX-3117 is an oral, small molecule cytidine analog anticancer agent with an improved pharmacological… 
2019
2019
Background/Aim: The novel cytidine analog RX-3117, which is activated by uridine-cytidine kinase 2 (UCK2), shows encouraging… 
Review
2019
Review
2019
420 Background: RX-3117 is an oral small molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by cancer… 
2017
2017
Background: A novel, orally bioavailable nucleoside analogue, RX-3117, is a prodrug activated intracellularly by Uridine Cytidine… 
2016
2016
Fluorocyclopentenylcytosine (RX-3117) is an orally available cytidine analog, currently in Phase I clinical trial. RX-3117 has… 
2016
2016
ABSTRACT RX-3117 (fluorocyclopentenyl-cytosine) is a novel cytidine analog currently being evaluated in a Phase Ib clinical trial… 
2015
2015
Fluorocyclopentenylcytosine (RX-3117) is an orally bioavailable novel cytidine analog, currently being tested in a Phase I… 
2014
2014
RX-3117 (fluorocyclopentenylcytosine) is a cytidine analog and this class of drugs, including gemcitabine, has been widely used… 
Review
2014
Review
2014
  • G. Peters
  • Nucleosides, nucleotides & nucleic acids
  • 2014
  • Corpus ID: 205855349
Antimetabolites are the most widely used and most efficacious group of anticancer drugs. Antimetabolites are also the oldest… 
2013
2013
SummaryA novel cytidine analog fluorocyclopentenylcytosine (RX-3117; TV-1360) was characterized for its cytotoxicity in a 59-cell…